WellPoint, Inc. (WLP), CIGNA Corporation (CI): Will Obamacare Deliver a Crushing Blow to the Middle Class?

Page 1 of 2

Tick-tock, tick-tock, tick-tockjust six-and-half more months until the Patient Protection and Affordable Care Act, also known as Obamacare, goes into full effect.

Over the past year we at The Motley Fool have examined the ins-and-outs of this bill from multiple angles, including how a cap on the medical loss ratio at 80% will ensure patients who need medical care are getting it, and that no patient can be turned away for preexisting conditions. However, we’ve also looked at the other side of the coin, which demonstrates there’s a strong possibility that health insurers will maintain much of their pricing leverage that would most likely lead to continued premium hikes.

WellPoint, Inc. (NYSE:WLP)

As I’ve said before, one of the few certainties about the PPACA is that uncertainties reign! Questions abound as to how it will affect the quality and price of care received, as well as impact the individual pocketbooks of consumers around the U.S. Perhaps no issue, though, is more pressing than how the bill will affect the middle-class American consumer.

Some will like this bill

Source: LaDawna Howard on Flickr.

This isn’t to say that lower-income individuals are going to unanimously be in favor of Obamacare, but the fact of the matter is that the PPACA will almost certainly provide them with better quality care. The Medicaid expansion will bring approximately 16 million currently uninsured people into the government-run program, and beefed up minimum health plan requirements will ensure a steady level of care even for our nation’s lower income individuals.

This is one of the primary reasons we witnessed WellPoint, Inc. (NYSE:WLP) and CIGNA Corporation (NYSE:CI) jockeying for position in the Medicaid arena by purchasing AMERIGROUP and HealthSpring, respectively, in 2012 and 2011. Government-run health care may not provide the beefiest margins, but it’s more than made up for with the sheer volume of new Medicaid patients expected to enter the system next year.

Some won’t…
The viewpoint of upper-income earners with regard to the rollout of Obamacare isn’t likely to be as enthusiastic. Just as upper-income earners pay the majority of taxes in this country, they’ll be responsible for 40% of all new tax revenue from Obamacare, according to estimates by the Christian Science Monitor. A 0.9% tax surcharge on income up to $200,000 ($250,000 for a family of four) and a 3.8% tax on unearned income of more than $250,000 (e.g., dividends and capital gains) will certainly go a long way to helping pay for this Medicaid expansion. Despite an unpopular viewpoint among the rich, this tax isn’t likely to be a backbreaker for this income group.

And others will be crushed whether they like it or not!
The real concern I have stems for the middle class, which could see a conglomeration of problems derived from the implementation of Obamacare.

The bill itself has failsafes in place to ensure that it isn’t a burden to the middle-class consumer. Specifically, subsidies up to 400% of the federal poverty level — which equates to roughly $46,000 for an individual or $94,200 for a family of four — are in place to help curb rate shock for middle-class individuals who fall under the $46,000 range. But what happens to those individuals who are considered middle class and make $46,000 to, say, $70,000 a year? I’d propose that there’s a potential they’re going to get crushed!

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!